Allspring Global Investments Holdings LLC Sells 77,738 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 51.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,858 shares of the biopharmaceutical company's stock after selling 77,738 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.13% of Vanda Pharmaceuticals worth $354,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA bought a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $864,000. Geode Capital Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company's stock valued at $6,689,000 after buying an additional 94,870 shares during the period. Barclays PLC lifted its stake in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after buying an additional 86,677 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company's stock valued at $292,000 after buying an additional 57,393 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Vanda Pharmaceuticals by 7.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company's stock valued at $3,663,000 after buying an additional 55,567 shares during the period. 88.14% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the business's stock in a transaction dated Friday, February 28th. The stock was bought at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the purchase, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders bought 22,000 shares of company stock worth $100,980. Insiders own 8.90% of the company's stock.

Vanda Pharmaceuticals Trading Up 1.3 %

NASDAQ:VNDA traded up $0.06 during mid-day trading on Friday, hitting $4.76. The company's stock had a trading volume of 487,887 shares, compared to its average volume of 653,259. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.71 and a fifty-two week high of $6.75. The company has a market capitalization of $277.58 million, a price-to-earnings ratio of -14.88 and a beta of 0.74. The stock has a fifty day moving average of $4.59 and a 200-day moving average of $4.80.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. On average, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on VNDA. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright increased their price target on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.